Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMT NASDAQ:HRMY NYSE:NUVB NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$11.60+11.3%$9.47$3.68▼$12.34$544.72M2.75871,418 shs2.07 million shsHRMYHarmony Biosciences$34.16+2.2%$31.63$25.52▼$40.87$1.94B0.96786,509 shs467,839 shsNUVBNuvation Bio$6.04+4.9%$4.87$1.81▼$9.75$2.01B1.524.26 million shs4.60 million shsSTOKStoke Therapeutics$31.11+0.5%$31.79$11.17▼$40.22$1.93B1.17577,291 shs1.18 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics+7.87%+13.02%+21.16%+13.51%+152.30%HRMYHarmony Biosciences+0.45%-2.19%+10.88%+23.36%+4.83%NUVBNuvation Bio+4.15%+12.24%+22.22%+35.09%+195.40%STOKStoke Therapeutics-0.10%+3.23%+5.56%-3.76%+167.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$11.60+11.3%$9.47$3.68▼$12.34$544.72M2.75871,418 shs2.07 million shsHRMYHarmony Biosciences$34.16+2.2%$31.63$25.52▼$40.87$1.94B0.96786,509 shs467,839 shsNUVBNuvation Bio$6.04+4.9%$4.87$1.81▼$9.75$2.01B1.524.26 million shs4.60 million shsSTOKStoke Therapeutics$31.11+0.5%$31.79$11.17▼$40.22$1.93B1.17577,291 shs1.18 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics+7.87%+13.02%+21.16%+13.51%+152.30%HRMYHarmony Biosciences+0.45%-2.19%+10.88%+23.36%+4.83%NUVBNuvation Bio+4.15%+12.24%+22.22%+35.09%+195.40%STOKStoke Therapeutics-0.10%+3.23%+5.56%-3.76%+167.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.67Moderate Buy$29.88157.54% UpsideHRMYHarmony Biosciences 2.27Hold$40.8919.70% UpsideNUVBNuvation Bio 2.55Moderate Buy$12.50106.95% UpsideSTOKStoke Therapeutics 2.73Moderate Buy$41.8334.47% UpsideCurrent Analyst Ratings BreakdownLatest FDMT, NUVB, STOK, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026NUVBNuvation Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/22/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)5/11/2026STOKStoke Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/8/2026FDMT4D Molecular Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/8/2026HRMYHarmony Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$25.00 ➝ $29.005/5/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.005/5/2026NUVBNuvation Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.005/5/2026NUVBNuvation Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/1/2026HRMYHarmony Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$88.24M6.87N/AN/A$8.85 per share1.31HRMYHarmony Biosciences$868.45M2.28$3.25 per share10.51$15.11 per share2.26NUVBNuvation Bio$143.05M14.70N/AN/A$0.88 per share6.86STOKStoke Therapeutics$184.42M10.51N/AN/A$6.17 per share5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$140.11M-$2.57N/AN/AN/A-182.34%-36.83%-32.55%8/10/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4813.779.380.2316.20%17.19%11.99%8/4/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%8/11/2026 (Estimated)Latest FDMT, NUVB, STOK, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026FDMT4D Molecular Therapeutics-$0.97-$1.01-$0.04-$1.01$2.59 million$3.05 million5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A9.349.34HRMYHarmony Biosciences0.153.583.56NUVBNuvation Bio0.157.447.24STOKStoke TherapeuticsN/A8.998.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%HRMYHarmony Biosciences86.23%NUVBNuvation Bio61.67%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics7.90%HRMYHarmony Biosciences11.00%NUVBNuvation Bio30.11%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12052.28 million48.15 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionableSTOKStoke Therapeutics10062.28 million56.37 millionOptionableFDMT, NUVB, STOK, and HRMY HeadlinesRecent News About These CompaniesStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $43,637.15 in StockJune 21 at 4:42 AM | americanbankingnews.comJonathan Allan Sells 1,457 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 19, 2026 | insidertrades.comGranahan Investment Management LLC Has $6.08 Million Stock Position in Stoke Therapeutics, Inc. $STOKJune 17, 2026 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 15, 2026 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from AnalystsJune 15, 2026 | marketbeat.comRhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOKJune 13, 2026 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Up 1.6% - Should You Buy?June 12, 2026 | marketbeat.comStoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.com4 Biotech Stocks Investors Should Watch in 2026June 5, 2026 | zacks.comStoke Therapeutics Stockholders Approve Directors and Governance ItemsJune 4, 2026 | tipranks.comStoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?June 4, 2026 | zacks.comBarry Ticho Sells 1,795 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 4, 2026 | insidertrades.comStoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business UpdatesJune 1, 2026 | insidermonkey.comStoke Therapeutics to Present at Upcoming Investor Conferences in JuneMay 29, 2026 | finance.yahoo.comIs it a Good Idea to Invest in Stoke Therapeutics Stock Now?May 21, 2026 | zacks.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 | businesswire.comStoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent ResultsMay 12, 2026 | finance.yahoo.comStoke Therapeutics, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Guardant Health (GH) and Stoke Therapeutics (STOK)May 10, 2026 | theglobeandmail.comStoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balanceMay 8, 2026 | seekingalpha.comStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFDMT, NUVB, STOK, and HRMY Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$11.60 +1.18 (+11.32%) Closing price 04:00 PM EasternExtended Trading$11.78 +0.19 (+1.59%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Harmony Biosciences NASDAQ:HRMY$34.16 +0.73 (+2.18%) Closing price 04:00 PM EasternExtended Trading$34.15 -0.01 (-0.03%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Nuvation Bio NYSE:NUVB$6.04 +0.28 (+4.86%) Closing price 03:58 PM EasternExtended Trading$6.02 -0.02 (-0.33%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Stoke Therapeutics NASDAQ:STOK$31.11 +0.14 (+0.45%) As of 04:00 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
